Reminder: Transgenomic to Hold Fourth Quarter Financial Results Conference Call Today
OMAHA, Neb.--(BUSINESS WIRE)-- Transgenomic, Inc. (OTCBB: TBIO) today announced the following Webcast:
|
| What: |
|
|
|
Transgenomic, Inc. Fourth Quarter 2012 Financial Results and Business Update Conference Call |
| |
| When: |
|
|
|
Wednesday, March 13, 2013 @ 5:00 p.m. Eastern |
| |
| Where: |
|
|
|
http://www.transgenomic.com/events.asp?id=6
|
| |
| How: |
|
|
|
Live over the Internet -- Simply log on to the web at the address above. |
| |
| Contact: |
|
|
|
Investor Relations, 402-452-5416 |
|
|
|
|
|
To access the call via telephone, dial 866-952-1906 from the U.S. and Canada or 785-424-1825 for international participants and enter conference ID TRANS. A telephone replay will be available from 6:00 p.m. Eastern Time on March 13, 2013 through 11:59 p.m. Eastern Time on March 27, 2013 by dialing 800-723-0520 (domestic) or 402-220-2653 (international).
About Transgenomic, Inc.
Transgenomic, Inc. (www.transgenomic.com) is a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through its proprietary molecular technologies and world-class clinical and research services. The Company is a global leader in cardiac genetic testing with a family of innovative products, including its C-GAAP test, designed to detect gene mutations which indicate cardiac disorders, or which can lead to serious adverse events. Transgenomic has three complementary business divisions: Transgenomic Clinical Laboratories, which specializes in molecular diagnostics for cardiology, oncology, neurology, and mitochondrial disorders; Transgenomic Pharmacogenomic Services, a contract research laboratory that specializes in supporting all phases of pre-clinical and clinical trials for oncology drugs in development; and Transgenomic Diagnostic Tools, which produces equipment, reagents, and other consumables that empower clinical and research applications in molecular testing and cytogenetics. Transgenomic believes there is significant opportunity for continued growth across all three businesses by leveraging their synergistic capabilities, technologies, and expertise. The Company actively develops and acquires new technology and other intellectual property that strengthens its leadership in personalized medicine.
Investor Contact
Argot Partners
David Pitts, 212-600-1902
david@argotpartners.com
or
Company Contact
Transgenomic, Inc.
Investor Relations
402-452-5416
investorrelations@transgenomic.com
KEYWORDS: United States North America Nebraska
INDUSTRY KEYWORDS:
RSS Headlines
Fool UK